Location: Boston, MA
CIK: 0001637359 · Show all filings
Period: Q4 2025 (← Previous) (Next →)
Filing Date: Feb 17, 2026
Total Value: $287M (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| NUVB | Nuvation Bio | 8,081,089 | $72.41M | 25.3% | $11.18 | -44.6% | Common Stock Class A | 67080N101 |
| BBOT | BridgeBio Oncology Therapeutics Inc. | 3,289,661 | $41.19M | 14.4% | $11.58 | — | Common Stock | 107924102 |
| BBNX | Beta Bionics Inc. | 1,316,183 | $40.1M | 14.0% | $18.64 | +43.2% | Common Stock | 08659B102 |
| BCAX | Bicara Therapeutics Inc. | 2,204,650 | $37.1M | 12.9% | $25.50 | -33.0% | Common Stock | 055477103 |
| KMTS | Kestra Med Technologies Ltd | 1,373,591 | $36.43M | 12.7% | $22.98 | +12.1% | Common Stock | G52441105 |
| UPB | Upstream Bio Inc. | 1,326,293 | $36.01M | 12.6% | $22.33 | +11.5% | Common Stock | 91678A107 |
| ENGN | enGene Holdings Inc. | 876,357 | $7.914M | 2.8% | $9.45 | -15.2% | Common Stock | 29286M105 |
| ALMS | Alumis Inc. | 653,223 | $6.375M | 2.2% | $13.30 | -47.5% | Common Stock | 022307102 |
| SANA | Sana Biotechnology, Inc. | 843,750 | $3.434M | 1.2% | $32.56 | -86.2% | Common Stock | 799566104 |
| IMA | ImageneBio, Inc. | 455,361 | $3.142M | 1.1% | $13.25 | -44.1% | Common Stock | 45175G207 |
| REPL | Replimune Group | 248,672 | $2.417M | 0.8% | $17.40 | -51.1% | Common Stock | 76029N106 |